A Phase 3 interventional study of IPTp-sulphadoxine-pyrimethamine plus metronidazole and IPTp-dihydroartemisinin-piperaquine plus metronidazole in Pregnancy Malaria, Bacterial Vaginoses and Trichomonas Vaginitis, sponsored by London School of Hygiene and Tropical Medicine. Completed at 1 site in Zambia. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-22.
Sponsored by London School of Hygiene and Tropical Medicine · Phase 3, Interventional, and Prevention
Among 21 studies testing metronidazole in Vaginosis, Bacterial — 2 open to participants now, 2 under way, 1 of them phase 3. Metronidazole · Vaginosis, Bacterial.
Among the 21 studies testing metronidazole in Vaginosis, Bacterial, this one has the largest enrollment, is one of 2 that started in 2019, is one of 4 in phase 3, and was the 18th registered.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
Browse Vaginosis, Bacterial studies →2 of the 21 studies testing metronidazole in Vaginosis, Bacterial are open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+ · Healthy volunteers
Assistance Publique Hopitaux De Marseille
Ages 18+ · Women only
By country, each count listing its studies:
Metronidazole: first FDA approval 1963 (FLAGYL). What it is approved for, and how studies give it, is on its page →
Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4 · Phase 4 9
First in 2002; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,436 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Median enrollment 166 across the 21 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.
London School of Hygiene and Tropical Medicine has 2 studies filed under Vaginosis, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing metronidazole in Vaginosis, Bacterial, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Malaria in pregnancy has devastating consequences for mother and foetus. WHO recommends intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) for asymptomatic women, but high-level parasite resistance to SP threatens its efficacy. Dihydroartemisinin-piperaquine (DP) has the potential to replace SP for IPTp. However, the DP strategy has not been found to be superior to SP for reducing the incidence of low birthweight (LBW), small-for-gestational age (SGA), or preterm birth. This may be the result of sulphadoxine having antibacterial properties; it is derived from sulphonamide, which have been used for decades to treat curable STIs/RTIs. However, SP is unlikely to be curative of STIs/RTIs, nor highly effective against malaria parasites. Thus, combination treatment that contains a more efficacious antimalarial and a more efficacious anti-STI/RTI may produce better birth outcomes. The investigators will therefore determine whether combining SP with metronidazole (MTZ) or, separately, DP with MTZ can improve birth outcomes more than SP alone, potentially paving the way for integrated control strategies that will reduce the dual burden of malaria and curable STIs/RTIs.
This is an individually-randomized, 3-arm, partially-placebo controlled superiority trial comparing the efficacy, safety and tolerance of IPTp-SP versus IPTp-SP with MTZ, or IPTp-DP with MTZ to reduce adverse birth outcomes attributable to malaria and curable STIs/RTIs in 5,436 women in the Nchelenge District of Zambia.
Title: Effects of metronidazole plus intermittent preventive treatment of malaria in pregnancy on birth outcomes: a randomised controlled trial in Zambia.
Short Title: The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract
Background and rationale: Current interventions in sub-Saharan Africa to reduce the burden of malaria infection and curable STIs/RTIs in pregnancy are inadequate. Malaria infection during pregnancy is responsible for 20% of all stillbirths and 11% of neonatal deaths and is strongly associated with low birthweight (LBW), preterm birth, and small-for-gestational-age (SGA) babies. To protect against adverse pregnancy outcomes in malaria-endemic areas, the WHO recommends providing IPTp-SP to pregnant women at each scheduled ANC visit as directly observed therapy from the second trimester to delivery with at least one month between doses. However, the loss of parasite sensitivity to SP has compromised the efficacy of IPTp.
Apart from syphilis and HIV screening, the WHO recommends the syndromic management of curable STIs/RTIs in low- and middle-income countries involving diagnostic and treatment algorithms based on self-reported symptoms. BV and TV are included in these guidelines. However, syndromic management fails to detect the majority of infections in women for whom STIs/RTIs are most often asymptomatic. This is of genuine consequence in pregnancy. BV is the most common urogenital disorder in the world among women of reproductive age and increases the odds of preterm delivery 1.5-2 times. TV is the most prevalent curable STI in the world and increases the odds of preterm delivery 1.5 times. BV and TV both double the odds of LBW. Although vertical transmission of TV is uncommon, maternal treatment may prevent respiratory or genital infection of the newborn. These adverse pregnancy outcomes could be averted with metronidazole (MTZ); 2g is safe and curative of TV and reduces the recurrence of BV. Importantly, the dose can be provided as directly observed therapy during ANC to ensure compliance.
IPTp-DP is the leading candidate to replace IPTp-SP. A trial in Kenya showed that IPTp-DP was superior to IPTp-SP in preventing clinical malaria episodes and other malaria-related endpoints. Alongside the trial, the investigators will conduct sub-studies that will generate important data about the mechanisms of IPTp-SP action against malaria, BV and TV.
Primary objective: To determine if IPTp with SP or DP, combined with MTZ, for the control of malaria and STIs/RTIs in pregnancy is safe and superior to IPTp with SP alone for reducing adverse pregnancy outcomes.
Hypothesis: IPTp with SP or DP, combined with MTZ, is superior to IPTp with SP alone in preventing adverse pregnancy outcomes.
Overview Study Design: A 3-arm, parallel, partially placebo-controlled, individually randomised, phase-3, superiority trial involving 5,436 (1,812 per arm) pregnant women in ANC facilities of the Nchelenge District of Zambia.
An economic evaluation will be carried out alongside the trial to estimate the cost and cost-effectiveness of interventions. In addition, the acceptability of therapy and the trade-offs between different attributes of the trial arms will be assessed using a discrete choice framework among trial participants and health care providers.
Sub-study 1: Effect of treatment on vaginal and intestinal microbiome and maternal cytokines
Objective: To characterise the effect of treatment across trial arms on the vaginal and intestinal microbiota communities, vaginal and intestinal bacterial loads and soluble markers of inflammation.
Sub-study 2: In vitro testing of sulphadoxine and other antimicrobial agents (Ndola, Zambia)
Objective: To measure the drug sensitivity of several pathogens implicated with WHO syndromes of vaginal discharge, lower abdominal pain, or genital ulcers in the presence of sulphadoxine and other antimicrobial agents.
Sites: The study will be conducted ANC facilities of the Nchelenge District of Zambia where the prior pregnancy cohort was previously carried out, malaria transmission is high, parasite resistance to SP is high, and there is a high prevalence of TV and BV among pregnant women at antenatal care facilities.
Study Population: HIV-negative pregnant women (all gravidae) between 16 and 28 weeks' gestation, as assessed by ultrasound dating who have not yet started IPTp during the current pregnancy.
Study Interventions:
Group 1: IPTp-SP plus MTZ placebo* (control) Group 2: IPTp-SP plus MTZ* Group 3: IPTp-DP plus MTZ*
SP = 3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine (Day 0) MTZ = 4 tablets each containing 500mg as directly observed therapy (Day 0) DP = 3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine (Days 0, 1, 2)
*MTZ placebo (Group 1) and active MTZ (Groups 2 and 3) will be co-administered with SP or DP during the enrolment visit (gestational week 16-19) and the last ANC visit prior to delivery (gestational week 30-34)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
Drug: IPTp-sulphadoxine-pyrimethamine
3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
Drug: IPTp-sulphadoxine-pyrimethamine plus metronidazole
3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
Drug: IPTp-dihydroartemisinin-piperaquine plus metronidazole
Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
Also known as: Fansidar, Flagyl
Drug page: Metronidazole
Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
Also known as: Flagyl, D-ARTEPP®
The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
Also known as: Fansidar
Adverse pregnancy outcome
Composite endpoint of foetal morbidity, defined as any of the following: foetal loss (spontaneous abortion or stillbirth), singleton live births born with low birthweight (LBW), or preterm (PT) (LBW-PT), and subsequent neonatal death by day 28.
Time frame: 8 months
Individual components of the primary outcome- adverse pregnancy outcomes
Prevalence of individual components of primary outcome
Time frame: 8 months
Foetal loss
Spontaneous abortion or stillbirth (binary)
Time frame: 8 months
Neonatal mortality
Death in the first 28 days of life (binary)
Time frame: 8 months
Low birthweight
Birthweight \<2.5 kg (binary)
Time frame: 8 months from randomisation
Preterm birth
Birth at \<37 gestational weeks
Time frame: 8 months from randomisation
Birth weight (continuous)
Weight at birth (g)
Time frame: 8 months from randomisation
Gestational age at delivery (continuous)
Based on gestational age measured by ultrasound at enrolment (days)
Time frame: 8 months from randomisation
Z-score for birthweight (continuous)
Z-score for birthweight (g) from regional population reference
Time frame: 8 months from randomisation
Small for gestational age (binary)
Estimated as a stand-alone secondary outcome using the 10th percentile of regional reference charts on the corrected birthweight
Time frame: 8 months from randomisation
Clinical malaria during pregnancy (binary)
Clinical malaria at any point from enrolment including delivery and 28 day postpartum, both: * Documented fever (≥37.5°C), or recent history of fever in the past 24 hours, or other symptoms of acute illness that resulted in a woman seeking care with an unscheduled visit * Maternal malaria patent infection detectable by Rapid Diagnostic Test (RDT) for women with malaria symptoms only
Time frame: 8 months from randomisation
Maternal malaria infection (binary)
Malaria infection detected by PCR during pregnancy in the peripheral blood at any point during pregnancy (scheduled and unscheduled visits) from study registration, including delivery.
Time frame: 8 months from randomisation
Any malaria at delivery (binary)
Malaria infection at delivery detected in peripheral blood by PCR or placental blood by microscopy, PCR or histology (active infection)
Time frame: 8 months from randomisation
Placental malaria infection (binary)
Placental malaria detected by microscopy, PCR , or histology (active and past infection) including any Plasmodium species detected in the placental blood or biopsy tissue by either: * Placental incision smear microscopy (standard microscopy) * PCR placental blood (maternal) * Placental malaria by histology (active and past infection)
Time frame: 8 months from randomisation
Congenital malaria infection (binary)
Malaria infection detected in foetal cord blood of the new born at birth by standard microscopy
Time frame: 8 months from randomisation
Placental malaria by histology (binary)
* Active Infection: 1. Chronic: pigment present and asexual parasites present 2. Acute: pigment absent and asexual parasites present * Past Infection: Pigment in fibrin detected in the absence of asexual parasites. * Placental histology categories 1. Any 2. Active 3. Active acute 4. Active chronic 5. Past
Time frame: 8 months from randomisation
Placental Inflammation or chorioamnionitis (binary)
Any inflammation in the placenta or chorioamnionitis detected by placental histology
Time frame: 8 months from randomisation
Maternal anaemia (binary) and haemoglobin concentration (continuous (g/dL) at enrolment and delivery
Definition: * No anaemia (Hb \>11 g/dL) * Mild (Hb \>10 to \<11 g/dL) * Moderate (Hb \>7 to \<10 g/dL * Severe (Hb \<7 g/dL)
Time frame: 8 months from randomisation
Congenital anaemia in umbilical cord blood at delivery
Hb\<12.5 g/dL in umbilical cord blood at birth, which is 2 standard deviations below the mean cord Hb in developed countries
Time frame: 8 months from randomisation
Congenital malformations (binary)
Physical abnormality of live born baby detected at delivery or newly noted abnormality during the infant visits (7 days or 2-6 weeks post-natal)
Time frame: 8 months from randomisation
Maternal mortality (binary)
Maternal mortality from registration until 28 days after delivery
Time frame: 8 months from randomisation
SAEs and AEs defined by MedDRA (listings)
AEs and SAEs will be defined according to the Medical Dictionary for Regulatory Activities (MedDRA) and reported by study arm: * Overall * By system organ class and preferred term
Time frame: 8 months from randomisation
History of vomiting study drug - Prevalence at each cycle of treatment (binary)
Vomited within 30 minutes of taking study drug at any scheduled administration
Time frame: 8 months from randomisation
Dizziness - Prevalence at each cycle of treatment
Dizziness at any point within 30 minutes of first drug administered during a treatment cycle, reported as Mothers adverse event
Time frame: 8 months from randomisation
Gastrointestinal complaints - Prevalence at each cycle of treatment (binary)
Nausea or vomiting within 30 minutes of first drug administered during a treatment cycle
Time frame: 8 months from randomisation
Presence of any one or more STIs/RTIs - Prevalence at enrolment (binary)
Any or more infection of syphilis, gonorrhoea, chlamydia, trichomoniasis, and bacterial vaginosis
Time frame: 8 months from randomisation
Plan to share: Yes — Individual participant data will be shared upon receiving formal request and subject to sharing agreement.
Supporting information: Study protocol
Time frame: Five years
Access criteria: The full protocol will be available on request to any interested professional. All requests for data for secondary analysis will be considered by a Data Access Committee to ensure that use of data is within the terms of consent and ethics approval.
No publications or documents are linked to this record.
Ran from Dec 2019 to primary completion in Oct 2022, 34 months.
Of 12 phase 3 interventional studies under Vaginosis, Bacterial, half reached primary completion within 9 months of starting (the median); a quarter within 5 and three quarters within 25. This study's 34 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole
London School of Hygiene and Tropical Medicine →